This prominent pharmaceutical stock could attract more investors as market conditions fluctuate.
Currently, you may have observed that financial markets are experiencing significant volatility. This observation holds true for various sectors, including stocks, cryptocurrencies, and commodities.
In times of market turbulence, many investors tend to retreat to safer options. Some opt to liquidate their assets and hold cash, while others pursue investment opportunities in more stable sectors. For instance, value stocks within industries that typically thrive during volatile conditions can be particularly appealing to numerous investors.
This leads us to discuss Pfizer (PFE +0.72%). Could this be the optimal value stock to acquire during periods of market volatility?
Image source: Getty Images.
Understanding Pfizer’s Resilience Against Market Volatility
As previously mentioned, Pfizer possesses certain qualities that contribute to its resilience during volatile market periods. Typically, healthcare stocks exhibit better performance compared to many other sectors during challenging economic times. This trend arises from a fundamental reality: individuals require various healthcare products and services regardless of prevailing economic conditions. Consequently, this leads to consistent revenue streams and profits for companies operating within the healthcare sector.
Consider Pfizer’s array of top-selling blockbuster medications. Would a physician stop prescribing Eliquis for patients experiencing blood clots simply because of market instability? Are patients diagnosed with transthyretin-mediated amyloidosis (ATTR) likely to discontinue their use of Vyndamax due to fluctuations in the market? The answer to both questions is a resounding no.
Additionally, Pfizer’s dividend yield enhances its attractiveness to investors seeking refuge during turbulent times. With a forward dividend yield of an impressive 6.9%, investors can find solace knowing that Pfizer is generating ample free cash flow to maintain these dividend payments.
Perhaps the most convincing evidence of Pfizer’s stability amidst market fluctuations is its five-year monthly beta of only 0.43. A lower beta value indicates reduced volatility in comparison to the overall market, making Pfizer a compelling choice for investors seeking stability.
Assessing Pfizer as a True Value Stock
This may seem like an odd inquiry, but is Pfizer genuinely a value stock? Currently, its shares are trading at a forward price-to-earnings (P/E) ratio of 8.3. This figure is lower than Pfizer’s historical average and represents only a fraction of the healthcare sector’s forward earnings multiple of 18.2. However, there are two significant points of contention regarding whether Pfizer can truly be classified as a value stock.
Firstly, the company’s growth prospects are somewhat questionable. Pfizer is approaching a significant patent cliff, which poses a challenge. For instance, the autoimmune disease treatment Xeljanz and the blood thinner Eliquis will lose their U.S. patent protection next year. Although generic competitors for Eliquis will not enter the market until 2028, this patent expiration raises concerns. Additionally, breast cancer medication Ibrance and prostate cancer treatment Xtandi will lose patent exclusivity in 2027.
Today’s Change
(0.72%) $0.18
Current Price
$25.22
Essential Data Points
Market Cap
$143B
Day’s Range
$25.05 – $25.47
52wk Range
$20.91 – $27.69
Volume
28K
Avg Vol
67M
Gross Margin
69.53%
Dividend Yield
6.82%
Secondly, the company’s substantial debt complicates the situation further. Valuation metrics based on enterprise value might provide a clearer picture of Pfizer’s standing. While the pharma stock does not appear overly expensive based on its enterprise value-to-EBITDA ratio of 10.2, it does not seem as cheap as the forward earnings multiple would imply.
Nevertheless, I consider Pfizer a value stock. I also believe it is not a value trap. The company has a diverse portfolio of products that do not face exclusivity losses in the near term, along with promising late-stage pipeline candidates that should significantly offset the expected revenue declines arising from its patent cliff.
In particular, Pfizer’s recent acquisitions have positioned it more favorably to navigate the challenges posed by its upcoming exclusivity losses. The latest acquisition involves the buyout of Metsera for up to $10 billion (approximately $7 billion upfront, with the remainder contingent on meeting specific clinical and regulatory milestones). This strategic deal has the potential to establish Pfizer as a significant player in the lucrative obesity drug market.
Evaluating Pfizer as the Top Value Stock Amid Market Uncertainty
So, is Pfizer the leading value stock to purchase during heightened market volatility? I would not definitively claim that. There are other strong contenders in the market, and to be honest, I have not conducted thorough research on all of them.
However, I do believe that Pfizer stands out as a solid value stock to consider during turbulent market conditions. The appeal of its ultra-high-yield dividend is hard to overlook. Additionally, I am optimistic about the company’s growth prospects, which appear better than they may initially seem.
